Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.

Thrombosis research - 1 Sept 2009

Palmirotta Raffaele, Ferroni Patrizia, Savonarola Annalisa, Martini Francesca, Ciatti Filippo, Laudisi Anastasia, Sini Valentina, Del Monte Girolamo, Guadagni Fiorella, Roselli Mario

Abstract excerpt

INTRODUCTION: Plasminogen activator inhibitor (PAI-1) may have an independent prognostic value in breast cancer (BC). PAI-1 4G/5G polymorphism may have significance for antigen expression. Thus, we analyzed the possible associations between PAI-1 4G/5G polymorphism, plasma PAI-1 levels, and clinicopathological features of breast cancer (BC) patients. PATIENTS AND METHODS: PAI-1 4G/5G polymorphism (both on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Plasminogen Activator Inhibitor 1

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Recurrence

Share to Survival Rate

Source

Identifiers

PMID: 19351570
DOI: 10.1016/j.thromres.2009.02.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.PMID 19351570Read ↗

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.Semantic proximity Read ↗

Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.Semantic proximity Read ↗

Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.Semantic proximity Read ↗

Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.Semantic proximity Read ↗

Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.Semantic proximity Read ↗

PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.Semantic proximity Read ↗

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.Semantic proximity Read ↗

PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.Semantic proximity Read ↗

[Association of single nucleotide polymorphisms in PAI-1 with breast cancer susceptibility and prognosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.